Evidence map›Paper›PMID 32990984›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2021

A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow-Fed Young Adult Mice.

Michela Palmieri, Ha-Neui Kim, Horacio Gomez-Acevedo, Xuchu Que, Sotirios Tsimikas, Robert L Jilka, Stavros C Manolagas, Joseph L Witztum, Elena Ambrogini

Open access · hybridAbstract read
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Obesity and lipid metabolism in the development of osteoporosis (Review).International journal of molecular medicine · 2024
    Review
  5. Oxidized phospholipids in cardiovascular disease.Nature reviews. Cardiology · 2024
    Review
  6. Review
  7. Article
  8. Review
  9. The OSE complotype and its clinical potential.Frontiers in immunology · 2022
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Michela PalmieriDivision of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases and Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, USA.
Ha-Neui KimDivision of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases and Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, USA.ORCID 0000-0003-2498-6700
Horacio Gomez-AcevedoDepartment of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Xuchu QueDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Sotirios TsimikasDivision of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Robert L JilkaDivision of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases and Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, USA.
Stavros C ManolagasDivision of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases and Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, USA.ORCID 0000-0002-0826-3484
Joseph L WitztumDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Elena AmbroginiDivision of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases and Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, USA.ORCID 0000-0002-5704-6072
Central Arkansas Veterans Healthcare System · USUniversity of California San Diego · USUniversity of Arkansas for Medical Sciences · US

Funding

Transcriptional GenomicsP01HL088093 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WITZTUM, JOSEPH L. · 2008 to 2018
$26.4M
TRANSGENIC MOUSE COREP01AG013918 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI O'BRIEN, CHARLES A · 1996 to 2016
$25.7M
Project 4: APOB-specific CD4 and CD8 T cells exacerbate atherosclerosisP01HL136275 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Catherine C Hedrick · 2017 to 2026
$25.5M
Understanding the Negative Prognostic Impact of Intraosseous Focal Lesions in Multiple MyelomaP20GM125503 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI CHARLES A O'BRIEN · 2018 to 2026
$23.0M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR029884 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI LOWERY, CURTIS L · 2009 to 2011
$11.4M
Pivotal Role of Oxidation-specific Epitopes in CVD and NASHR01HL148188 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WITZTUM, JOSEPH L. · 2019 to 2019
$551k
Role of Natural Antibodies Against Oxidation Specific Epitopes in Bone HomeostasisI01BX003901 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI Elena Ambrogini · 2019 to 2026
–
Estrogens, androgens, aging, and bone loss in malesI01BX001405 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI MANOLAGAS, STAVROS C. · 2012 to 2021
–
BLRD VA I01 BX001405BLRD VA I01 BX003901NHLBI NIH HHS P01 HL088093NHLBI NIH HHS P01 HL136275NHLBI NIH HHS R01 HL148188NIA NIH HHS P01 AG013918NIGMS NIH HHS P20 GM125503
6 · The paper itself

Abstract

Oxidized phospholipids containing phosphocholine (OxPL) are pro-inflammatory lipid peroxidation products that bind to scavenger receptors (SRs), such as Scarb1, and toll-like receptors (TLRs). Excessive OxPL, as found in oxidized low-density lipoprotein (OxLDL), overwhelm these defense mechanisms and become pathogenic in atherosclerosis, nonalcoholic steatohepatitis (NASH), and osteoporosis. We previously reported that the innate IgM natural antibody E06 binds to OxPL and neutralizes their deleterious effects; expression of the single-chain (scFv) form of the antigen-binding domain of E06 (E06-scFv) as a transgene increases trabecular bone in male mice. We show herein that E06-scFv increases trabecular and cortical bone in female and male mice by increasing bone formation and decreasing osteoblast apoptosis in vivo. Homozygous E06-scFv mice have higher bone mass than hemizygous, showing a dose effect of the transgene. To investigate how OxPL restrain bone formation under physiologic conditions, we measured the levels of SRs and TLRs that bind OxPL. We found that osteoblastic cells primarily express Scarb1. Moreover, OxLDL-induced apoptosis and reduced differentiation were prevented in bone marrow-derived or calvaria-derived osteoblasts from Scarb1 knockout mice. Because Scarb1-deficient mice are reported to have high bone mass, our results suggest that E06 may promote bone anabolism in healthy young mice, at least in part, by neutralizing OxPL, which in turn promote Scarb1-mediated apoptosis of osteoblasts or osteoblast precursors. © 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)..

Indexed as

OsteogenesisPhospholipidsAnimalsAntibodies, NeutralizingFemaleMaleMiceMice, KnockoutOxidation-ReductionAntibodies, NeutralizingPhospholipidsANABOLICSBONE MODELING AND REMODELINGCELLS OF BONEMOLECULAR PATHWAYS-REMODELINGOSTEOBLASTSTHERAPEUTICS

Identifiers

PMID32990984
PMCPMC7855899
OpenAlexW3091147100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.